ACTU Actuate Therapeutics Inc.

Price (delayed)

$1.91

Market cap

$45.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.97

Enterprise value

$37.56M

?
Relative Growth: Rel. Growth: 18
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We ...

Highlights
The EPS has surged by 75% year-on-year and by 8% since the previous quarter
ACTU's net income is up by 15% YoY and by 3.1% from the previous quarter
Actuate Therapeutics's equity has soared by 174% YoY but it has plunged by 52% from the previous quarter
Actuate Therapeutics's quick ratio has decreased by 26% from the previous quarter

Key stats

What are the main financial stats of ACTU

ACTU stock price

How has the Actuate Therapeutics stock price performed over time
Intraday
4.95%
1 week
-8.17%
1 month
-35.25%
1 year
-79.03%
YTD
-68.79%
QTD
-30.29%

Financial performance

How have Actuate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.84M
Net income
-$21.54M
Gross margin
N/A
Net margin
N/A
ACTU's net income is up by 15% YoY and by 3.1% from the previous quarter
Actuate Therapeutics's operating income has increased by 8% YoY and by 2.9% from the previous quarter

Price vs fundamentals

How does ACTU's price correlate with its fundamentals

Growth

What is Actuate Therapeutics's growth rate over time

Valuation

What is Actuate Therapeutics stock price valuation
P/E
N/A
P/B
11.97
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 75% year-on-year and by 8% since the previous quarter
Actuate Therapeutics's equity has soared by 174% YoY but it has plunged by 52% from the previous quarter

Efficiency

How efficient is Actuate Therapeutics business performance
Actuate Therapeutics's ROA has increased by 47% YoY and by 12% from the previous quarter
Actuate Therapeutics's ROE has increased by 46% from the previous quarter

Dividends

What is ACTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACTU.

Financial health

How did Actuate Therapeutics financials performed over time
Actuate Therapeutics's total assets is 74% higher than its total liabilities
Actuate Therapeutics's total assets has surged by 99% YoY but it has decreased by 37% QoQ
The total liabilities has contracted by 46% YoY and by 16% from the previous quarter
ACTU's debt is 100% lower than its equity
Actuate Therapeutics's equity has soared by 174% YoY but it has plunged by 52% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.